Feasibility of Modeling Stable Warfarin Dose
Warfarin is a commonly used drug that prevents hypercoagulation. However, there is a high rate of adverse effects for patients on Warfarin since it has a narrow therapeutic window and each person’s dose is individually determined. Individual variability is due, in part to differences in the genetics of each individual as well as differences in body size, medications, and medical conditions. Marshfield Clinical Research Foundation has previously developed a model that explains about 56% of the dose variability in Caucasians. In a small pilot clinical study of prospective Warfarin dosing, using the model was better than the standard of care. Since there are currently no models available for African American individuals there is a need to develop appropriate dosing guidelines.
This pilot project will be implemented locally in 2 Aurora Health Care Centers for a total population of approximately 60 African American individuals.
The Wisconsin Network for Health Research (WiNHR) is sponsoring the study. WiNHR is a network of researchers interested in improving the health of Wisconsin through research.
December 2006 – December 2007
Investigators & Staff
Aurora Health Care
Matthew Tector, Ph.D.
Aurora UW Medical Group
Dennis Baumgardner, M.D.
Center for Urban Population Health
Jennifer Evertsen, M.S.
Melissa Lemke, B.A